Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution

The deposition of proteins in the form of amyloid fibrils and plaques is the characteristic feature of more than 20 degenerative conditions affecting either the central nervous system or a variety of peripheral tissues. As these conditions include Alzheimer's, Parkinson's and the prion diseases, several forms of fatal systemic amyloidosis, and at least one condition associated with medical intervention (haemodialysis), they are of enormous importance in the context of present-day human health and welfare. Much remains to be learned about the mechanism by which the proteins associated with these diseases aggregate and form amyloid structures, and how the latter affect the functions of the organs with which they are associated. A great deal of information concerning these diseases has emerged, however, during the past 5 years, much of it causing a number of fundamental assumptions about the amyloid diseases to be re-examined. For example, it is now apparent that the ability to form amyloid structures is not an unusual feature of the small number of proteins associated with these diseases but is instead a general property of polypeptide chains. It has also been found recently that aggregates of proteins not associated with amyloid diseases can impair the ability of cells to function to a similar extent as aggregates of proteins linked with specific neurodegenerative conditions. Moreover, the mature amyloid fibrils or plaques appear to be substantially less toxic than the pre-fibrillar aggregates that are their precursors. The toxicity of these early aggregates appears to result from an intrinsic ability to impair fundamental cellular processes by interacting with cellular membranes, causing oxidative stress and increases in free Ca2+ that eventually lead to apoptotic or necrotic cell death. The 'new view' of these diseases also suggests that other degenerative conditions could have similar underlying origins to those of the amyloidoses. In addition, cellular protection mechanisms, such as molecular chaperones and the protein degradation machinery, appear to be crucial in the prevention of disease in normally functioning living organisms. It also suggests some intriguing new factors that could be of great significance in the evolution of biological molecules and the mechanisms that regulate their behaviour.

[1]  C. Levinthal Are there pathways for protein folding , 1968 .

[2]  G. Glenner,et al.  Creation of "Amyloid" Fibrils from Bence Jones Proteins in vitro , 1971, Science.

[3]  I. Nagy,et al.  Protein and water contents of aging brain. , 1982, Experimental brain research.

[4]  H. Pelham Speculations on the functions of the major heat shock and glucose-regulated proteins , 1986, Cell.

[5]  O. Ptitsyn,et al.  The ‘molten globule’ state is involved in the translocation of proteins across membranes? , 1988, FEBS letters.

[6]  R. Ellis,et al.  The molecular chaperone concept. , 1989, Biochemical Society symposium.

[7]  Ellis Rj The molecular chaperone concept. , 1990 .

[8]  J. Kelly,et al.  Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. , 1992, Biochemistry.

[9]  E. Rojas,et al.  Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. Rojas,et al.  Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Pedersen,et al.  Defective protein folding as a basis of human disease. , 1995, Trends in biochemical sciences.

[13]  W. Honer,et al.  Correlations of synaptic and pathological markers with cognition of the elderly , 1995, Neurobiology of Aging.

[14]  S. Schmid,et al.  Dynamin self-assembles into rings suggesting a mechanism for coated vesicle budding , 1995, Nature.

[15]  M. Mullan,et al.  β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.

[16]  B. Kagan,et al.  Pore Formation by the Cytotoxic Islet Amyloid Peptide Amylin (*) , 1996, The Journal of Biological Chemistry.

[17]  M. Mattson,et al.  Aβ25–35 induces rapid lysis of red blood cells: contrast with Aβ1–42 and examination of underlying mechanisms , 1997, Brain Research.

[18]  B. Kagan,et al.  Channel Formation by a Neurotoxic Prion Protein Fragment* , 1997, The Journal of Biological Chemistry.

[19]  M. Reilly Genetically determined neuropathies , 1997, Journal of Neurology.

[20]  Christopher M. Dobson,et al.  Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis , 1997, Nature.

[21]  D. Walsh,et al.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.

[22]  S. Aota,et al.  Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module. , 1998, Journal of molecular biology.

[23]  A K Dunker,et al.  Thousands of proteins likely to have long disordered regions. , 1998, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.

[24]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I D Campbell,et al.  Amyloid fibril formation by an SH3 domain. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Kelly,et al.  The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. , 1998, Current opinion in structural biology.

[27]  S. Lindquist,et al.  Hsp90 as a capacitor for morphological evolution , 1998, Nature.

[28]  Genetic polymorphisms in Parkinson's disease. , 1998, Neurotoxicology.

[29]  S. Linse,et al.  Molecular Characterization of α–Lactalbumin Folding Variants That Induce Apoptosis in Tumor Cells* , 1999, The Journal of Biological Chemistry.

[30]  C. Dobson Protein misfolding, evolution and disease. , 1999, Trends in biochemical sciences.

[31]  J. Thyberg,et al.  Amyloid fibril formation by pulmonary surfactant protein C , 1999, FEBS letters.

[32]  R. Plemper,et al.  Retrograde protein translocation: ERADication of secretory proteins in health and disease. , 1999, Trends in biochemical sciences.

[33]  J. Kourie,et al.  Synthetic mammalian C‐type natriuretic peptide forms large cation channels , 1999, FEBS letters.

[34]  M Bycroft,et al.  Hot-spot mutants of p53 core domain evince characteristic local structural changes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Selkoe,et al.  Title Amyloid β-protein fibrillogenesis . Structure and biological activity of protofibrillar intermediates , 1999 .

[36]  Christopher M Dobson,et al.  From Computer Simulations to Human Disease Emerging Themes in Protein Folding , 1999, Cell.

[37]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[38]  F. Stevens,et al.  Pathogenic light chains and the B-cell repertoire. , 1999, Immunology today.

[39]  H. Wiśniewski,et al.  Alteration of free radical metabolism in the brain of mice infected with scrapie agent. , 1999, Free radical research.

[40]  C M Dobson,et al.  Designing conditions for in vitro formation of amyloid protofilaments and fibrils. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Lansbury,et al.  Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. , 1999, Biochemistry.

[42]  Peter T. Lansbury,et al.  Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease† , 1999 .

[43]  Morgan Bp Regulation of the complement membrane attack pathway. , 1999 .

[44]  B. Morgan Regulation of the complement membrane attack pathway. , 1999, Critical reviews in immunology.

[45]  A. Goldberg,et al.  The Sizes of Peptides Generated from Protein by Mammalian 26 and 20 S Proteasomes , 1999, The Journal of Biological Chemistry.

[46]  H. Dyson,et al.  Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. , 1999, Journal of molecular biology.

[47]  M. Mattson Impairment of membrane transport and signal transduction systems by amyloidogenic proteins. , 1999, Methods in enzymology.

[48]  H. Lin,et al.  Amyloid beta protein (1-40) forms calcium-permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. , 1999, Biochemistry.

[49]  Elena Orlova,et al.  Cryo‐electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing , 1999, The EMBO journal.

[50]  M. Feder,et al.  Natural hyperthermia and expression of the heat shock protein Hsp70 affect developmental abnormalities in Drosophila melanogaster , 1999, Oecologia.

[51]  S. Prusiner,et al.  Transmissible and genetic prion diseases share a common pathway of neurodegeneration , 1999, Nature.

[52]  R. Lal,et al.  Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: evidence for AβP channel‐mediated cellular toxicity , 2000 .

[53]  Jonathan W. Yewdell,et al.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.

[54]  C M Dobson,et al.  Ultrastructural organization of amyloid fibrils by atomic force microscopy. , 2000, Biophysical journal.

[55]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[56]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[57]  P. Frederikse Amyloid-like protein structure in mammalian ocular lenses. , 2000, Current eye research.

[58]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Hai Lin,et al.  Fresh and nonfibrillar amyloid β protein(1–40) induces rapid cellular degeneration in aged human fibroblasts: evidence for AβP‐channel‐mediated cellular toxicity , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  L. Serpell,et al.  The protofilament substructure of amyloid fibrils. , 2000, Journal of molecular biology.

[61]  M. Michalak,et al.  Perforin Lytic Activity Is Controlled by Calreticulin1 , 2000, The Journal of Immunology.

[62]  E. Wanker,et al.  Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  H. Zoghbi,et al.  Identification of genes that modify ataxin-1-induced neurodegeneration , 2000, Nature.

[64]  H. True,et al.  A yeast prion provides a mechanism for genetic variation and phenotypic diversity , 2000, Nature.

[65]  L. Regan,et al.  A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Hecht,et al.  Nature disfavors sequences of alternating polar and non-polar amino acids: implications for amyloidogenesis. , 2000, Journal of molecular biology.

[67]  H. Budka,et al.  Evidence for Oxidative Stress in Experimental Prion Disease , 2000, Neurobiology of Disease.

[68]  T. Bek Ocular changes in heredo-oto-ophthalmo-encephalopathy , 2000, The British journal of ophthalmology.

[69]  R. Kopito,et al.  Aggresomes and Russell bodies , 2000, EMBO reports.

[70]  W. Markesbery,et al.  Decreased levels of proteasome activity and proteasome expression in aging spinal cord , 2000, Neuroscience.

[71]  W. Markesbery,et al.  Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.

[72]  D. F. Andrews,et al.  A one-hit model of cell death in inherited neuronal degenerations , 2000, Nature.

[73]  Masahiro Kawahara,et al.  Alzheimer's β-Amyloid, Human Islet Amylin, and Prion Protein Fragment Evoke Intracellular Free Calcium Elevations by a Common Mechanism in a Hypothalamic GnRH Neuronal Cell Line* , 2000, The Journal of Biological Chemistry.

[74]  J. Neefjes,et al.  The major substrates for TAP in vivo are derived from newly synthesized proteins , 2000, Nature.

[75]  A. Monji,et al.  Inhibition of Aβ fibril formation and Aβ-induced cytotoxicity by senile plaque-associated proteins , 2000, Neuroscience Letters.

[76]  Hyun-pil Lee,et al.  Induction of heme oxygenase-1 in the brains of scrapie-infected mice , 2000, Neuroscience Letters.

[77]  H. Minakata,et al.  Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. , 2000, Biophysical journal.

[78]  D. Butterfield,et al.  Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. , 2000, Journal of structural biology.

[79]  L. Serpell,et al.  Alzheimer's amyloid fibrils: structure and assembly. , 2000, Biochimica et biophysica acta.

[80]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[81]  M. Cheetham,et al.  Unfolding retinal dystrophies: a role for molecular chaperones? , 2001, Trends in molecular medicine.

[82]  Bing-sheng Li,et al.  α-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway , 2001, Neuroscience Letters.

[83]  D. Allsop,et al.  alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. , 2001, Free radical biology & medicine.

[84]  C. Dobson,et al.  Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation , 2001, Protein science : a publication of the Protein Society.

[85]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[86]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[87]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[88]  C. Dobson,et al.  Detection of two partially structured species in the folding process of the amyloidogenic protein beta 2-microglobulin. , 2001, Journal of molecular biology.

[89]  H. Lehrach,et al.  Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. , 2001, Molecular biology of the cell.

[90]  M. Spillantini,et al.  α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.

[91]  M. Al-Habori,et al.  Macromolecular crowding and its role as intracellular signalling of cell volume regulation. , 2001, The international journal of biochemistry & cell biology.

[92]  J. Kourie,et al.  Channel activity of deamidated isoforms of prion protein fragment 106–126 in planar lipid bilayers , 2001, Journal of neuroscience research.

[93]  N. Cairns,et al.  Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. , 2001, Biochemical and biophysical research communications.

[94]  P. Csermely,et al.  Chaperone overload is a possible contributor to 'civilization diseases'. , 2001, Trends in genetics : TIG.

[95]  J Lowe,et al.  The ubiquitin protein catabolic disorders , 2001, Neuropathology and applied neurobiology.

[96]  Rui M. M. Brito,et al.  Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin Variants* , 2001, The Journal of Biological Chemistry.

[97]  S. Bhakdi,et al.  Membrane insertion of the heptameric staphylococcal alpha-toxin pore. A domino-like structural transition that is allosterically modulated by the target cell membrane. , 2001, The Journal of biological chemistry.

[98]  H. Braak,et al.  Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. , 2001, Journal of Alzheimer's disease : JAD.

[99]  M. Greenberg,et al.  β-Amyloid Induces Neuronal Apoptosis Via a Mechanism that Involves the c-Jun N-Terminal Kinase Pathway and the Induction of Fas Ligand , 2001, The Journal of Neuroscience.

[100]  D. Rubinsztein,et al.  Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. , 2001, Human molecular genetics.

[101]  Membrane Insertion of the Heptameric Staphylococcal α-Toxin Pore , 2001, The Journal of Biological Chemistry.

[102]  Rushana Azimova,et al.  The channel hypothesis of Huntington’s disease , 2001, Brain Research Bulletin.

[103]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[104]  C. Dobson,et al.  Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N‐terminal domain , 2001, Protein science : a publication of the Protein Society.

[105]  M. F. Perutz,et al.  Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats , 2001, Nature.

[106]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[107]  E. Williamson,et al.  Hsp70 and Antifibrillogenic Peptides Promote Degradation and Inhibit Intracellular Aggregation of Amyloidogenic Light Chains , 2001, The Journal of cell biology.

[108]  J. Bartek,et al.  Order from Destruction , 2001, Science.

[109]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[110]  D. Butterfield,et al.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. , 2001, Trends in molecular medicine.

[111]  A. Miranker,et al.  Kidney dialysis-associated amyloidosis: a molecular role for copper in fiber formation. , 2001, Journal of molecular biology.

[112]  M. Parker,et al.  The cholesterol-dependent cytolysins. , 2001, Current topics in microbiology and immunology.

[113]  J. King,et al.  Frequencies of amino acid strings in globular protein sequences indicate suppression of blocks of consecutive hydrophobic residues , 2001, Protein science : a publication of the Protein Society.

[114]  Mark A. Smith,et al.  Induction of NADPH cytochrome P450 reductase by the Alzheimer β‐protein. Amyloid as a ‘foreign body’ , 2001, Journal of neurochemistry.

[115]  A. Goldberg,et al.  Cellular Defenses against Unfolded Proteins A Cell Biologist Thinks about Neurodegenerative Diseases , 2001, Neuron.

[116]  C Capanni,et al.  Folding and Aggregation Are Selectively Influenced by the Conformational Preferences of the α-Helices of Muscle Acylphosphatase* , 2001, The Journal of Biological Chemistry.

[117]  R. Ellis,et al.  Macromolecular crowding: an important but neglected aspect of the intracellular environment. , 2001, Current opinion in structural biology.

[118]  O. Matsushita,et al.  Cleavage of a C-terminal Peptide Is Essential for Heptamerization of Clostridium perfringens ε-Toxin in the Synaptosomal Membrane* , 2001, The Journal of Biological Chemistry.

[119]  T. Squier,et al.  Oxidative stress and protein aggregation during biological aging , 2001, Experimental Gerontology.

[120]  C. Dobson The structural basis of protein folding and its links with human disease. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[121]  Juan R. Granja,et al.  Antibacterial agents based on the cyclic d,l-α-peptide architecture , 2001, Nature.

[122]  R. Lal,et al.  Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[123]  I. Conlon,et al.  Extracellular control of cell size , 2001, Nature Cell Biology.

[124]  C. Yip,et al.  Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption. , 2001, Biophysical journal.

[125]  U. Schlötzer-Schrehardt,et al.  Analysis of aqueous humour proteins of eyes with and without pseudoexfoliation syndrome , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.

[126]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[127]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[128]  M. Sousa,et al.  Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. , 2001, The American journal of pathology.

[129]  B. Kagan,et al.  Pore formation by beta-2-microglobulin: A mechanism for the pathogenesis of dialysis associated amyloidosis , 2001, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[130]  M. Nakanishi,et al.  A degradation signal located in the C‐terminus of p21WAF1/CIP1 is a binding site for the C8 α‐subunit of the 20S proteasome , 2001, The EMBO journal.

[131]  A. Rauk,et al.  The radical model of Alzheimer's disease: Specific recognition of Gly29 and Gly33 by Met35 in a β-sheet model of Aβ: An ONIOM study , 2002 .

[132]  S. Ji,et al.  Cholesterol Is an Important Factor Affecting the Membrane Insertion of β-Amyloid Peptide (Aβ1–40), Which May Potentially Inhibit the Fibril Formation* , 2002, The Journal of Biological Chemistry.

[133]  L. Tjernberg,et al.  Charge Attraction and β Propensity Are Necessary for Amyloid Fibril Formation from Tetrapeptides* , 2002, The Journal of Biological Chemistry.

[134]  H. Zoghbi,et al.  Mouse and fly models of neurodegeneration. , 2002, Trends in genetics : TIG.

[135]  P. Lansbury,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[136]  P. Wesseling,et al.  Collagen XVIII: a Novel Heparan Sulfate Proteoglycan Associated with Vascular Amyloid Depositions and Senile Plaques in Alzheimer's Disease Brains , 2002, Brain pathology.

[137]  R. Wetzel,et al.  Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. , 2002, Human Molecular Genetics.

[138]  Bin Liu,et al.  Microglia enhance β‐amyloid peptide‐induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species , 2002 .

[139]  Christopher M. Dobson,et al.  Protein-misfolding diseases: Getting out of shape , 2002, Nature.

[140]  J. Kemp,et al.  Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis , 2002, Nature.

[141]  F. Hartl,et al.  Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[142]  Fabrizio Chiti,et al.  Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[143]  V. Uversky Natively unfolded proteins: A point where biology waits for physics , 2002, Protein science : a publication of the Protein Society.

[144]  S. Lindquist,et al.  Neurotoxicity and Neurodegeneration When PrP Accumulates in the Cytosol , 2002, Science.

[145]  The radical model of Alzheimer's disease: specific recognition of Gly29 and Gly33 by Met35 in a beta-sheet model of Abeta: an ONIOM study. , 2002, Journal of Alzheimer's disease : JAD.

[146]  S. Lindquist,et al.  Hsp90 as a capacitor of phenotypic variation , 2002, Nature.

[147]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[148]  R. Wetzel Ideas of order for amyloid fibril structure. , 2002, Structure.

[149]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[150]  C. Dobson,et al.  Altered aggregation properties of mutant γ‐crystallins cause inherited cataract , 2002 .

[151]  Globular amyloid deposits in the wall of the gastrointestinal tract: report of six cases , 2002, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[152]  Andreas Hoenger,et al.  De novo designed peptide-based amyloid fibrils , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[153]  Christopher A Ross,et al.  Polyglutamine Pathogenesis Emergence of Unifying Mechanisms for Huntington's Disease and Related Disorders , 2002, Neuron.

[154]  G. Sobue,et al.  Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy , 2002, Neuron.

[155]  Kaushik Dutta,et al.  The regions of securin and cyclin B proteins recognized by the ubiquitination machinery are natively unfolded , 2002, FEBS letters.

[156]  Bin Zhang,et al.  Amyotrophic Lateral Sclerosis/Parkinsonism Dementia Complex: Transgenic Mice Provide Insights into Mechanisms Underlying a Common Tauopathy in an Ethnic Minority on Guam , 2002, Experimental Neurology.

[157]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[158]  N. Hattori,et al.  Effect of Wild-type or Mutant Parkin on Oxidative Damage, Nitric Oxide, Antioxidant Defenses, and the Proteasome* , 2002, The Journal of Biological Chemistry.

[159]  Christopher M. Dobson,et al.  The protofilament structure of insulin amyloid fibrils , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[160]  D. Czajkowsky,et al.  Monomer-Monomer Interactions Drive the Prepore to Pore Conversion of a β-Barrel-forming Cholesterol-dependent Cytolysin* , 2002, The Journal of Biological Chemistry.

[161]  Scott J. Hultgren,et al.  Role of Escherichia coli Curli Operons in Directing Amyloid Fiber Formation , 2002, Science.

[162]  P. Csermely,et al.  Chaperone function and chaperone overload in the aged. A preliminary analysis , 2002, Experimental Gerontology.

[163]  C. Olanow,et al.  Impairment of the ubiquitin‐proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures , 2002, Journal of neurochemistry.

[164]  N. Bonini Chaperoning brain degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[165]  P. Lansbury,et al.  Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? , 2002, Biochemistry.

[166]  R. Leapman,et al.  A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[167]  D. Allsop,et al.  Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. , 2002 .

[168]  S. Lehmann,et al.  Oxidative stress and the prion protein in transmissible spongiform encephalopathies , 2002, Brain Research Reviews.

[169]  Christopher A. Ross,et al.  Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization* , 2002, The Journal of Biological Chemistry.

[170]  M. Perutz,et al.  Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid β-peptide of amyloid plaques , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[171]  S. Radford,et al.  Crystal structure of monomeric human β-2-microglobulin reveals clues to its amyloidogenic properties , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[172]  F. Hartl,et al.  Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein , 2002, Science.

[173]  B. Kagan,et al.  Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense , 2002, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[174]  G. Pielak,et al.  FlgM gains structure in living cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[175]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[176]  Peter M. G. Munro,et al.  The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. , 2002, Journal of cell science.

[177]  J. Kourie,et al.  Ion channel formation and membrane‐linked pathologies of misfolded hydrophobic proteins: The role of dangerous unchaperoned molecules , 2002, Clinical and experimental pharmacology & physiology.

[178]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[179]  L. Serpell,et al.  Proteasomal degradation of tau protein , 2002, Journal of neurochemistry.

[180]  C. Link,et al.  Interaction of intracellular β amyloid peptide with chaperone proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[181]  P. Lansbury,et al.  Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. , 2002, Biochemistry.

[182]  Christopher M Dobson,et al.  Getting out of shape. , 2002, Nature.

[183]  D. Flood,et al.  Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model Is Associated with Amyloid Deposition , 2002, The Journal of Neuroscience.

[184]  D. Rubinsztein,et al.  Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. , 2002, Human molecular genetics.

[185]  J. Ávila,et al.  Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases , 2002, Peptides.

[186]  T. Walz,et al.  Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[187]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[188]  P. Moreira,et al.  Effect of amyloid beta-peptide on permeability transition pore: a comparative study. , 2002, Journal of neuroscience research.

[189]  D. Borchelt,et al.  High Molecular Weight Complexes of Mutant Superoxide Dismutase 1: Age-Dependent and Tissue-Specific Accumulation , 2002, Neurobiology of Disease.

[190]  J. Richardson,et al.  Natural β-sheet proteins use negative design to avoid edge-to-edge aggregation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[191]  K. Davies,et al.  Atherosclerosis: another protein misfolding disease? , 2002, Trends in molecular medicine.

[192]  A. Fersht,et al.  CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[193]  P. Moreira,et al.  Effect of amyloid β‐peptide on permeability transition pore: A comparative study , 2002 .

[194]  A. Macario,et al.  Sick chaperones and ageing: a perspective , 2002, Ageing Research Reviews.

[195]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[196]  S. Paul,et al.  Immunotherapy for Alzheimer's disease: will vaccination work? , 2003, Trends in Molecular Medicine.

[197]  C. Dobson Protein Folding and Disease: a view from the first Horizon Symposium , 2003, Nature Reviews Drug Discovery.

[198]  Melissa S Kosinski-Collins,et al.  In vitro unfolding, refolding, and polymerization of human γD crystallin, a protein involved in cataract formation , 2003, Protein science : a publication of the Protein Society.

[199]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[200]  C. Dennis Epigenetics and disease: Altered states , 2003, Nature.

[201]  J. Kourie Mechanisms of Amyloid β Protein-Induced Modification in Ion Transport Systems: Implications for Neurodegenerative Diseases , 2001, Cellular and Molecular Neurobiology.

[202]  D. Noonan Altered states. , 2004, Newsweek.